secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024727
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Q3 net loss $30.0M; FDA clears two INDs, halts PRMT5 internal development
--------------------------------------------------------------------------------

- Net loss of $30.0M ($0.63 per share) vs $30.7M ($0.66) in Q3 2021.
- Cash, equivalents & marketable securities $224.0M; runway into Q4 2024.
- FDA cleared INDs for PRT3789 (SMARCA2 degrader) and PRT3645 (brain-penetrant CDK4/6 inhibitor).
- Discontinues internal PRMT5 program (PRT543, PRT811) to focus on higher-potential assets.
- PRT2527 CDK9 Phase 1 dose escalation on track for RP2D by year-end; no dose reduction AEs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017022024727/0000950170-22-024727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017022024727/prld-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer